Strides Pharma Science · NSE: STAR · BSE: 532531

Q3 FY24 results · Oct–Dec 2023

Strides Pharma Science reported revenue from operations of ₹1,037.67 crore (up 20.0% from Q3 FY23) and net profit of ₹54.06 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY24	Q3 FY23	YoY	Q2 FY24	QoQ
Revenue from operations	1,037.67	864.85	+20.0%	999.43	+3.8%
Other income	8.75	26.20	−66.6%	35.85	−75.6%
Total income	1,046.42	891.05	+17.4%	1,035.28	+1.1%
Profit before share of associates & JVs and tax	61.99	65.44	−5.3%	(114.64)	Turned profit
Share of profit/(loss) of associates & JVs	(51.97)	(143.45)		(42.25)
Net profit for the period	54.06	(82.11)	Turned profit	(149.46)	Turned profit
Attributable to shareholders of the company	49.67	(80.03)	Turned profit	(131.34)	Turned profit
EPS, basic (₹)	5.43	(8.86)	Turned profit	(14.54)	Turned profit
Net margin (%)	5.2	-9.5		-15.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY24	Q3 FY23	YoY	Q2 FY24	QoQ
Revenue from operations	520.01	386.51	+34.5%	540.29	−3.8%
Other income	8.69	29.75	−70.8%	22.34	−61.1%
Total income	528.70	416.27	+27.0%	562.63	−6.0%
Profit before tax	3.52	17.99	−80.4%	4.19	−16.1%
Net profit for the period	2.54	12.54	−79.7%	1.28	+98.1%
EPS, basic (₹)	0.28	1.39	−79.9%	0.14	+100.0%
Net margin (%)	0.5	3.2		0.2

Consolidated

Filed with BSE: 31 Jan 2024, 09:41 IST
Board meeting: 30 Jan 2024
Period: 01 Oct 2023 to 31 Dec 2023
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 31 Jan 2024, 09:41 IST
Board meeting: 30 Jan 2024
Period: 01 Oct 2023 to 31 Dec 2023
Review status: Unaudited
Source: XBRL filing on BSE